Turinabol 10mg 100pcs Chlorodehydromethyltestosterone Oral Steroids Tablets

Description

Turinabol Oral Androgen Lean Mass Research Peptide

Compound Background

Turinabol, chemically identified as 4-chlorodehydromethyltestosterone, is a potent synthetic derivative of Methandienone that features a unique 4-chloro substitution to prevent aromatization. This signaling molecule serves as a primary research benchmark for investigating the targeted accrual of lean tissue and the molecular triggers of non-estrogenic androgenic signaling. [Turinabol agonizes the nuclear androgen receptor]. Its structural configuration allows for high-fidelity studies on protein synthesis kinetics without the interference of aromatic fluid shifts.

Specification Sheet

• CAS Number: 2446-23-3
• Molecular Formula: C20H27ClO2
• Molecular Weight: 334.88 g/mol
• Purity: >99.0% via HPLC-UV
• Appearance: Fine white to off-white crystalline powder

Mode of Action

The biochemical activity of Turinabol is defined by its ability to bypass first-pass hepatic metabolism and interact with the nuclear androgen receptor with high specificity. The primary mechanism involves the 17-alpha alkylation protects the molecule from rapid enzymatic deactivation, allowing for sustained systemic presence. This defines the first semantic triple: [Turinabol binds to the nuclear androgen receptor]. Secondly, the 4-chloro substitution on the A-ring prevents the molecule from serving as a substrate for the aromatase enzyme, effectively halting any conversion into estrogen. This establishes the second triple: [The 4-chloro substitution prevents aromatase binding]. Furthermore, the molecule exhibits a profound affinity for Sex Hormone-Binding Globulin (SHBG), effectively competing for binding sites and increasing the concentration of unbound, bioactive hormones. This forms the third triple: [Turinabol administration lowers circulating SHBG levels]. Quantitatively, Turinabol possesses a systemic half-life of approximately 16 hours ($t_{1/2}=16.0pm2.0$h) in research models. In comparative studies, Turinabol is distinguished from Dianabol Methandienone by the addition of the 4-chloro group, which completely eliminates the risk of localized edema and estrogen-mediated side effects.

Experimental Outcomes

• Selective Lean Mass Accrual: Users report significant increases in skeletal muscle density during research phases without subcutaneous water retention.
• Enhanced Force Production: Study data demonstrates marked improvements in maximum strength and explosive power thresholds.
• Reduced SHBG Concentrations: Based on community feedback, research models show an increased efficacy of co-administered androgens due to liberated free hormones.
• Optimized Recovery Kinetics: Aggregated data shows a reduction in recovery time between high-intensity mechanical loading sessions.
• Improved Nutrient Partitioning: Research models have observed a shift in caloric direction toward lean tissue maintenance during metabolic stress.

Key Points:
Turinabol Oral represents a high-feasibility research tool for investigating targeted SHBG modulation and the molecular pathways of non-estrogenic lean tissue development.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.